IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

Karim Chamie; Sam S. Chang; Eugene Kramolowsky; Mark L. Gonzalgo; Piyush Kumar Agarwal; Jeffrey C. Bassett; Marc Bjurlin; Michael L. Cher; William Clark; Barrett E. Cowan; Richard David; Evan Goldfischer; Khurshid Guru; Mark W. Jalkut; Samuel D. Kaffenberger; Jed Kaminetsky; Aaron E. Katz; Alec S. Koo; Wade J. Sexton; Sergei N. Tikhonenkov; Edouard J. Trabulsi; Andrew F. Trainer; Patricia Spilman; Megan Huang; Paul Bhar; Sharif A. Taha; Lennie Sender; Sandeep Reddy; Patrick Soon-Shiong

Journal ArticleOPEN ACCESS

IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

Chamie K
Chang S
Kramolowsky E
et al.

NEJM Evidence (2023) 2(1)

DOI: 10.1056/evidoa2200167

N/ACitations

43Readers

Abstract

Patients with Bacillus Calmette–Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC) have limited treatment options. The immune cell–activating interleukin-15 (IL-15) superagonist N...

Cite

CITATION STYLE

APA

Chamie, K., Chang, S. S., Kramolowsky, E., Gonzalgo, M. L., Agarwal, P. K., Bassett, J. C., … Soon-Shiong, P. (2023). IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer. NEJM Evidence, 2(1). https://doi.org/10.1056/evidoa2200167

IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

Abstract

Cite

Register to see more suggestions